Impact of MRSA on Ventilator-Associated Pneumonia
Author Information
Author(s): Shorr Andrew F, Tabak Ying P, Gupta Vikas, Johannes RS, Liu Larry Z, Kollef Marin H
Primary Institution: Washington Hospital Center
Hypothesis
What are the clinical and economic outcomes associated with MRSA infection in patients with early onset ventilator-associated pneumonia?
Conclusion
MRSA-related VAP is associated with increased hospital and ICU length of stay and higher costs compared to MSSA-related VAP.
Supporting Evidence
- MRSA patients had a longer overall length of stay compared to MSSA patients.
- MRSA was associated with increased ICU length of stay and total costs.
- Patients with MRSA were significantly older than those with MSSA.
Takeaway
This study shows that patients with a type of pneumonia caused by a resistant bacteria called MRSA stay in the hospital longer and cost more to treat than those with a different type of pneumonia.
Methodology
A retrospective cohort analysis was performed using data from 59 US hospitals over a 24-month period to assess clinical and economic outcomes of MRSA versus MSSA in patients with VAP.
Potential Biases
Coding practices for ICD-9-CM may vary across hospitals, introducing uncertainty in the findings.
Limitations
The study only included early onset VAP cases within five days of hospitalization, which may underestimate the prevalence of VAP and the impact of MRSA.
Participant Demographics
Patients with MRSA-related VAP were older, more likely to have comorbidities like congestive heart failure, and were primarily medical patients.
Statistical Information
P-Value
0.03
Confidence Interval
4.4 (0.6 to 8.2)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website